WO2004045537A2 - Edible film for relief of cough or symptoms associated with pharyngitis - Google Patents

Edible film for relief of cough or symptoms associated with pharyngitis Download PDF

Info

Publication number
WO2004045537A2
WO2004045537A2 PCT/US2003/036703 US0336703W WO2004045537A2 WO 2004045537 A2 WO2004045537 A2 WO 2004045537A2 US 0336703 W US0336703 W US 0336703W WO 2004045537 A2 WO2004045537 A2 WO 2004045537A2
Authority
WO
WIPO (PCT)
Prior art keywords
edible film
menthol
benzocaine
pectin
film
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/036703
Other languages
English (en)
French (fr)
Other versions
WO2004045537A3 (en
Inventor
R. Steven Davidson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zengen Inc
Original Assignee
Zengen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zengen Inc filed Critical Zengen Inc
Priority to AU2003295577A priority Critical patent/AU2003295577A1/en
Priority to CA002505833A priority patent/CA2505833A1/en
Priority to MXPA05005243A priority patent/MXPA05005243A/es
Priority to JP2004570422A priority patent/JP2006515598A/ja
Priority to EP03786775A priority patent/EP1560571A4/en
Publication of WO2004045537A2 publication Critical patent/WO2004045537A2/en
Publication of WO2004045537A3 publication Critical patent/WO2004045537A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Definitions

  • the present invention relates to edible films for relief of cough and/or
  • over-the-counter product for treatment of pharyngitis is a throat spray, where an active
  • ingredient is sprayed into the oral cavity of the user to provide temporary relief of
  • pharyngitis symptoms associated with pharyngitis such as throat pain, irritation, difficulty in
  • throat spray may be any suitable throat spray
  • the spray usually generates a noise drawing unwanted attention
  • the spray also requires the use of spray mechanisms and containers,
  • lozenges are not always desirable for
  • lozenge does not have the packaging costs of a spray or the
  • Lozenges can also be comprised of a candy filler material, as describe in
  • Such products may have other
  • an edible film for delivery of an active ingredient to or via the oral
  • present invention comprising an active ingredient wherein said active
  • ingredient comprising a mixture of essential oils and/or natural ingredients for the
  • present invention comprising an active pharmaceutical for the treatment of
  • present invention comprising an edible film having an active ingredient
  • the appropriate edible film carrier can be selected by one of ordinary
  • the film can also be thick
  • the desired rate for dissolution can vary depending of the specific
  • the film can be manufactured to rapidly dissolve in the oral cavity thus
  • the film can also be
  • Each film formulation usually comprises film formers, bulking agents,
  • softeners intense artificial sweeteners, sugar alcohol, natural sweeteners, flavors,
  • the film former which in most cases can be any water soluble film former.
  • Film formers include but are not limited to pullulan, guar gum, pectin, xanthan gum,
  • alginates gelatin, starches (including corn, potato, rice or tapioca), modified starches, matltodextrins, wheat gluten, carboxymethylcellulose, carrageenan konjac or locust
  • the active ingredient can be any active pharmaceutical. Such as
  • ingredients for the treatment of pharyngitis include but are not limited to menthol,
  • cough include but are not limited to the ingredients listed in Table 1. Specific
  • formulations of said ingredients may be selected by one of ordinary skill in the art
  • Agrimony agriminio eupatoria bistort (polygonum bistora) blue gum tree (eucalytus globulus) club moss (lycopodium clavatum) fenugreek garden thyme (thymus vulgaris) ginger golden seal (hydrastid candenis) kava kava lady's mantle (alchemilla vulgaris) lavender (lavedula spp.) Ingredient (Botanical name*) lobelia loosestrife (lythrum salicaria)
  • Marsh cudweed (gnophthalum uliginosum) myrrh (commiphora molmol) peppermint (mentha piperita) phosphorous poker root (phytolacca americana) pokeweed (phytolacca decandra) purple cone flower (echinacea puprea) purple sage (salvia officenalis)
  • Tree and Plant aloe sources bee pollen blackberry camphor oil cayenne elderberry gum arabic honey licorice extract maitake extract olive leaf extract sage oils sarsparilla sweet oil of birch shitake extract slippery elm Ingredient (Botanical name*) willow bark
  • Vitamins and co-enzyme Q10 minerals collodial silver vitamin C vitamin E zinc
  • Bacteria lactobacillus acidophilus Bacteria lactobacillus acidophilus
  • the film consists of one water soluble layer that serves as a
  • the substrate layer or active layer and a second dry coat layer.
  • the second dry coat layer is
  • ingredients may be contained in either layer, preferably the second dry coat layer will
  • dry coat layer is applied to the thin film surface after partial curing of the first (bottom)
  • the second layer can also contain substrates and
  • the film is of a size such that it is fast dissolving.
  • the weight per strip is of a size such that it is fast dissolving.
  • Said weight of the strip may be in the ranges of about 10 to 80 mg, about
  • the maximum dosing per strip may be 20 to 70 mg, about 30 to 60 mg and about 50 mg.
  • the maximum dosing per strip may be any dosing per strip.
  • Active ingredients can be delivered in a solid or liquid format and
  • the Active ingredients can be oil or water soluble. Active
  • the dosage per serving is 1-2 strips but may vary depending on the size of
  • the thickness of the first layer is preferably in
  • the thickness of the second dry coat is a range between about 0.040 to 1.1 micrometers.
  • the thickness of the layer is preferably in the range of about 0.007 to 0.02 micrometers.
  • the particularly layers may be more or less than the values recited herein depending on
  • Table 2 lists a formulation for a strip according to the present invention.
  • Pectin may be replaced by up to 5 % of one of the following: Gelatin, Maltodextrin, Modified Food Starch, TiO2, and Acacia Gum.
  • Said formulation will deliver approximately 3 mg of menthol and 3 mg
  • benzocaine per dose. Further, it may be advantage to include 15 to 20 % active
  • Table 3 lists a specific formulation for an edible film according to the
  • wt % is dry weight (finished film contains 8 to 10% moisture by weight)
  • the testing lasted two days. During testing the subjects were instructed
  • Table 5 shows subject demographics and test product randomization.
  • test material Batch #2:
  • This step includes aerating the mass prior to
  • the aeration step produces
  • a further embodiment of the present invention includes an improved
  • the film can be used on living cells.
  • Formation of the medicant-containing layer in the film does not require a solvent
  • Hydrophilic components can be
  • the present invention includes an improved composition for
  • the composition includes an applied coating
  • the film layer is made from any polymer, softener, filler, matrix, or
  • the film has an acceptable dissolution rate in the oral cavity for a
  • the film has a thickness of 50 microns, it has a thickness of 50 microns, it has a thickness of 50 microns, it has a thickness of 50 microns, it has a thickness of 50 microns, it has a thickness of 50 microns, it has a thickness of 50 microns, it has a thickness of 50 microns, it has a thickness of 50 microns, it has a thickness of 50 microns, it
  • the film may be desirable for the film to dissolve in the oral cavity within about fifteen
  • the film can be made with pullulan, modified starch,
  • pectin pectin, carageenan, a maltrodextrin, or alginate.
  • the applied coating is a powder matrix including one or more
  • the medicant can be contained in a powder carrier, or can itself be a
  • powder matrix is that it ordinarily does not require
  • auxiliary components can, if desired, include in addition to the medicant a variety of different auxiliary
  • compositions are provided.
  • a further advantage of the powder matrix is that it can be admixed in
  • dry air or another gas is dispersed upwardly through a plurality of openings to
  • the admixed powder matrix can also be stored (i.e., suspended) in the fluidized bed,
  • matrix can be applied in any desired manner, including sifting, screening,
  • the powder matrix can be atomized through a Nordson or similar static spray gun using compressed air.
  • One such gun creates a fine mist spray of powder particles.
  • the gun statically
  • particles is to admix the particles with a liquid carrier to form a particle — liquid
  • the particle — liquid solution is sprayed on the film layer.
  • the liquid carrier evaporates, leaving the powder particles on the film.
  • the powder particles preferably does not cause the powder particles to dissolve in the liquid carrier.
  • the medicant is a composition that dissolves slowly over a selected period of time.
  • an auxiliary dissolution control composition can be utilized to slow the release of
  • auxiliary composition examples of this kind of auxiliary composition are, without
  • gel forming compositions like carrageenan, gelatin, alignates, pullulan, PVP,
  • the fibers can comprise carboxymethylcellulose.
  • Another auxiliary composition the can be included in the powder matrix
  • an absorption composition that absorbs water or saliva.
  • auxiliary absorption composition can be also be used to slow the release of medicant
  • the gel can, if desired, cause the strip to become chewable
  • an auxiliary composition is termed a gel
  • the auxiliary composition absorbs at least four times it weight of water or of saliva or other aqueous solution in a selected period of time, or (2) the auxiliary composition
  • period of time can vary but preferably is from five seconds to fifteen minutes, most
  • gel auxiliary compositions include,
  • composition that, when placed in the oral cavity in contact with the mucosa therein,
  • the powder matrix can be adjusted to vary the length of time that the film adheres to the
  • auxiliary adhesion compositions adhere to the oral mucosa or to mucosa or tissue in
  • auxiliary adhesion compositions include carboxymethycellulose, polyvinyl alcohol,
  • polyvinyl pyrrolidone (povidone), sodiumalginate, methyl cellulose, hydroxyl propyl
  • cellulose hydroxypropylmethyl cellulose, polyethylene glycols, carbopol,
  • polycarbophil carboxyvinyl copolymers, propylene glycol alginate, alginic acid,
  • methyl methacrylate copolymers tragacanth gum, guar gum, karaya gum, ethylene
  • compositions are not listed.
  • matrix is a flow composition that, when subjected to a curing process, flows to form a
  • process is heating the film layer with powder coating to a selected temperature above
  • auxiliary composition are lipids (including various animal and vegetable
  • fats waxes, particularly low melting point waxes, and polyols, particularly low
  • melting point polyols that can be admixed in powder form or than can included be in
  • Combinations of auxiliary compositions can be included in the powder
  • dissolution of a medicant, less soluble fillers and fibers can be included in the powder
  • the powder matrix is normally administered to the film layer to form
  • the dry powder matrix will normally contain a minor amount of
  • the film layer can be produced
  • the polymer preferably has good film moldability, produces a soft flexible
  • One such polymer can be a water-soluble
  • cellulose derivative like hydroxypropyl cellulose (HPC), methyl cellulose,
  • the polymer can comprise an acrylic acid copolymer or its sodium,
  • the acrylic acid copolymer or its salt can be any organic compound having potassium or ammonium salt.
  • the acrylic acid copolymer or its salt can be any organic compound having potassium or ammonium salt.
  • the acrylic acid copolymer or its salt can be any organic compound having potassium or ammonium salt.
  • alginic acid or its salt poly-saccharide or its derivatives such as trangacanth, bum
  • gelatin collagen, denatured gelatin, and collagen treated with succinic acid or
  • anhydrous phthalic acid By way of example, the following can be included in the
  • powder matrix as adhesives poorly water-soluble cellulose derivatives including ethyl cellulose, cellulose acetate and butyl cellulose; shellac; higher fatty acids
  • steric acid and palmitic acid including steric acid and palmitic acid.
  • the following can also, without limitation,
  • Bulking agents that can be included in the powder matrix include, by:
  • avicel sugar alchohols including manitol and
  • the size of particulate in the powder matrix can vary as desired, but is
  • the ' thickness of the film layer can vary as desired, but typically is in
  • the powder matrix can be applied to one or both sides of the film
  • the film layer includes upper outer surface on the top of the film layer and
  • the upper outer surface is
  • the top of the film is generally parallel to the lower outer surface.
  • the top of the film is generally parallel
  • the thickness of the powder matrix layer can vary as
  • additional layer or layers can be applied over the powder matrix layer to seal the powder matrix layer, slow the dissolution of the medicant from the powder matrix
  • the film layer can comprise a laminate of two or more layers.
  • modifying agents, pigments, etc. in the film layer are well known in the art and not
  • compositions comprising the film layer is lessened.
  • the article may be placed in the mouth, oral cavity, on the
  • compositions and films of the present invention are identical to each other.
  • invention may contain at least one flavoring and/or odorant composition that renders
  • composition or film palatable Any effective flavor or odor may be used.
  • flavoring or odor agent or agents are present in any effective amount, including, for
  • the flavorings may be natural or artificial, or combinations
  • compositions and films of the present invention are identical to each other.
  • invention may contain at least one ingredient or agent that is pharmaceutically active. Any effective pharmaceutically active ingredient or agent may be used in any effective pharmaceutically active ingredient or agent.
  • agent may be present in any effective amount, including, for example, in an amount
  • predonisolone is added to the cellulose-alcohol solution to produce a film forming
  • the film forming composition is poured into a film molding frame
  • teflon plate placed on a teflon plate.
  • the area of teflon plate circumscribed by the frame is 9.5
  • the film forming composition is dried to form a film layer.
  • film layer includes an upper outer surface on top of the film layer and includes a
  • the film layer has a thickness of 40
  • Benzocaine powder (as a medicant) is combined with
  • carboxymethylcellulose powder as an adhesive
  • modified food starch as a bulking
  • carrageenan as adhesive
  • sucralose intense sweetener
  • talc as adhesive
  • the resulting powder matrix includes 3.76% by weight of
  • modified food starch 85.43% by weight of modified food starch, 3.76% by weight menthol, 2% by weight
  • the powder matrix is drawn from the fluidized bed container and is applied
  • the powder matrix is atomized through a Nordson or similar static
  • the gun statically electrically charges the powder particles so they
  • the powder matrix can also be any suitable powder matrix.
  • the powder matrix layer may be applied to the lower or bottom surface of the film layer.
  • the medicant composition comprises a medicant composition.
  • composition can be applied to mucous membrane at various areas of the body.
  • a film layer is prepared as follows. Xanthan gum (1.5% by weight),
  • locust bean gum (1.5% by weight), carrageenan (1 % by weight) and pullulan (9.5%
  • the gel is stored in a refrigerator overnight at a temperature of approximately
  • the film layer has a thickness of 55 microns.
  • carboxymethylcellulose powder as an adhesive
  • modified food starch as a bulking
  • carrageenan as adhesive
  • sucralose intense sweetener
  • talc as adhesive
  • menthol as a medicant
  • lipid in a fluidized-bed
  • the lipid is BENEF ATTM.
  • BENEF AT is
  • the resulting powder matrix includes 3.76% by
  • carrageenan 0.45% by weight sucralose, 2.0% by weight magnesium
  • the lipid preferably is in powder form.
  • the lipid initially is in liquid form, it can be plated on a particulate absorbent to
  • the particulate absorbent could, for example, be talc.
  • the powder matrix is drawn from the fluidized bed container and is
  • the powder matrix is atomized through a Nordson or similar static spray gun using compressed air.
  • the powder matrix layer and film layer together
  • the melting point of the lipid is close to temperature at which
  • the film layer is dried.
  • the film layer (along with the powder matrix
  • the layer applied to the film layer is typically dried at about 200 degrees F.
  • the lipid can melt and run off the film.
  • the medicant composition is cured using any desired heat treatment
  • the presently preferred process comprises a first step during which the
  • medicant composition is heated by a microwave or infrared transmitter. The time
  • spent by the medicant composition under the transmitter varies depending on the
  • microwave/infrared bombardment facilitates proper heating of the film layer by
  • the medicant composition is heated to 200 degrees F in a convection oven
  • medicant composition is in the convection oven can vary but is typically presently
  • the smoother powder matrix layer also improves the feel to an individual of the medicant composition in the mouth because the medicant
  • composition is not as dry on the tongue.
  • predonisolone is added to the cellulose-alcohol solution to produce a film forming
  • the film forming composition is poured into a film molding frame
  • teflon plate placed on a teflon plate.
  • the area of teflon plate circumscribed by the frame is 9.5
  • the film forming composition is dried to form a film layer.
  • film layer has a thickness of 50 microns.
  • carboxymethylcellulose powder (as a fiber adhesive), modified food starch (as a
  • the resulting powder matrix includes 3.76% by weight of benzocaine
  • modified food starch 5.0% by weight pullulan, 3.76% by weight menthol,
  • the filler, fiber, and polymer components of the powder matrix are:
  • composition is placed in the oral mucosa of an individual.
  • the powder matrix is drawn from the fluidized bed container and is
  • the powder matrix is atomized through a Nordson or similar

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2003/036703 2002-11-14 2003-11-14 Edible film for relief of cough or symptoms associated with pharyngitis Ceased WO2004045537A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003295577A AU2003295577A1 (en) 2002-11-14 2003-11-14 Edible film for relief of cough or symptoms associated with pharyngitis
CA002505833A CA2505833A1 (en) 2002-11-14 2003-11-14 Edible film for relief of cough or symptoms associated with pharyngitis
MXPA05005243A MXPA05005243A (es) 2002-11-14 2003-11-14 Pelicula comestible para el alivio de la tos o sontomas relacionados con la faringitis.
JP2004570422A JP2006515598A (ja) 2002-11-14 2003-11-14 咳または咽頭炎関連症状を軽減するための可食性フィルム
EP03786775A EP1560571A4 (en) 2002-11-14 2003-11-14 EDIBLE FILM FOR THE RELIEF OF COUGH OR SYMPTOMS ASSOCIATED WITH PHARYNGITIS

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42659802P 2002-11-14 2002-11-14
US60/426,598 2002-11-14
US49718603P 2003-08-22 2003-08-22
US60/497,186 2003-08-22

Publications (2)

Publication Number Publication Date
WO2004045537A2 true WO2004045537A2 (en) 2004-06-03
WO2004045537A3 WO2004045537A3 (en) 2004-07-15

Family

ID=32329116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036703 Ceased WO2004045537A2 (en) 2002-11-14 2003-11-14 Edible film for relief of cough or symptoms associated with pharyngitis

Country Status (7)

Country Link
US (1) US20040136923A1 (enExample)
EP (1) EP1560571A4 (enExample)
JP (1) JP2006515598A (enExample)
AU (1) AU2003295577A1 (enExample)
CA (1) CA2505833A1 (enExample)
MX (2) MXPA05005243A (enExample)
WO (1) WO2004045537A2 (enExample)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029896A1 (de) * 2004-09-17 2006-03-23 Aquanova German Solubilisate Technologies (Agt) Gmbh Konservierungsmittel-zusammensetzungen
WO2008104076A1 (en) * 2007-03-01 2008-09-04 Aroll Exama Electrocolloidal silver and echinacea root antimicrobial formulation
WO2008107301A2 (fr) 2007-02-28 2008-09-12 Pierre Fabre Medicament Film monocouche a desintegration rapide pour l'administration buccale de substances actives
WO2008089151A3 (en) * 2007-01-12 2009-03-19 Monosol Rx Llc High dose film compositions and methods of preparation
WO2009066262A1 (en) * 2007-11-21 2009-05-28 The Procter & Gamble Company Preparations, methods and kits useful for treatment of cough
WO2012135559A1 (en) * 2011-03-31 2012-10-04 Mcneil-Ppc, Inc. Menthol liquids composition
JP2012207031A (ja) * 2012-07-02 2012-10-25 Rohto Pharmaceutical Co Ltd 粘膜適用組成物
US8414922B2 (en) 2010-12-16 2013-04-09 Cynapsus Therapeutics, Inc. Sublingual films
ITMI20120510A1 (it) * 2012-03-29 2013-09-30 Bio Lo Ga Srl Vitamina e e suoi esteri per l'uso nel trattamento topico di affezioni faringo-laringee
WO2013167742A1 (fr) 2012-05-11 2013-11-14 Pierre Fabre Medicament Film monocouche a desintegration rapide et son utilisation dans l'hygiene buccale
US8652378B1 (en) 2001-10-12 2014-02-18 Monosol Rx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8906277B2 (en) 2001-10-12 2014-12-09 Monosol Rx, Llc Process for manufacturing a resulting pharmaceutical film
JP2015091888A (ja) * 2015-02-10 2015-05-14 ロート製薬株式会社 粘膜適用組成物
US9044475B2 (en) 2009-06-12 2015-06-02 Cynapsus Therapeutics, Inc. Sublingual apomorphine
US9108340B2 (en) 2001-10-12 2015-08-18 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
EP2990030A1 (en) 2014-08-27 2016-03-02 Nitto Denko Corporation Oral film-form base and preparation
JP2016121189A (ja) * 2016-04-01 2016-07-07 ロート製薬株式会社 粘膜適用組成物
US10272607B2 (en) 2010-10-22 2019-04-30 Aquestive Therapeutics, Inc. Manufacturing of small film strips
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US10449146B2 (en) 2015-04-21 2019-10-22 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
US10821074B2 (en) 2009-08-07 2020-11-03 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US11077068B2 (en) 2001-10-12 2021-08-03 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11191737B2 (en) 2016-05-05 2021-12-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
EP3810103A4 (en) * 2018-06-22 2022-02-16 Church & Dwight Co., Inc. Oral care compositions comprising benzocaine and mucoadhesive thin films formed therefrom
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
EP3893823A4 (en) * 2018-12-11 2022-11-02 Myospots Australia Pty Ltd Adhesive pad
WO2025106972A1 (en) * 2023-11-17 2025-05-22 Teeth Tabs PLLC Tableted effervescing dental treatment composition, and methods
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999372B2 (en) * 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
US20040191302A1 (en) 2003-03-28 2004-09-30 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US9561182B2 (en) * 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
US20040131662A1 (en) 2003-11-12 2004-07-08 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US8469036B2 (en) 2003-11-07 2013-06-25 U.S. Smokeless Tobacco Company Llc Tobacco compositions
DE102004050591A1 (de) * 2004-09-22 2006-04-06 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Schleimdrogenbasierte Lutschtablette gegen entzündliche Erkrankungen des Mund- und Rachenraums
EP1811980B1 (en) * 2004-09-30 2011-06-01 The Hershey Company Sealed, edible film strip packets and methods of making and using them
JP5116211B2 (ja) * 2005-03-03 2013-01-09 ロート製薬株式会社 粘膜適用組成物
CA2606724A1 (en) * 2005-05-03 2006-11-09 Innozen, Inc. Edible film for transmucosal delivery of nutritional supplements
DE102005053317B4 (de) * 2005-11-09 2007-10-18 Waltraud Zobel Verwendung einer Zusammensetzung mit einem Gemisch pflanzlicher Extrakte aus Fenchel, Thymian und Eukalyptus
WO2007102817A1 (en) * 2006-03-07 2007-09-13 Innozen, Inc. Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
US20080032032A1 (en) * 2006-08-01 2008-02-07 Pleva Raymond M Cherry-based additive
GB0625275D0 (en) * 2006-12-19 2007-01-24 Glaxo Group Ltd Novel process
GB0625429D0 (en) * 2006-12-20 2007-01-31 Mars Uk Ltd Composition
DE102006061287A1 (de) * 2006-12-22 2008-06-26 Lts Lohmann Therapie-Systeme Ag Eßbare folienförmige Zubereitung mit Cola-Geschmack
AU2008283805B2 (en) * 2007-08-02 2014-10-02 Monosol, Llc Carboxymethyl cellulose-based films, edible food casings made therefrom, and method of using same
EP2214478A1 (en) * 2007-10-19 2010-08-11 Innozen, Inc. Composition for administering an active ingredient and method for making and using the same
CN102014882A (zh) * 2008-01-31 2011-04-13 麦克内尔-Ppc股份有限公司 即刻释放活性成分的可食用膜条片
WO2010083227A1 (en) * 2009-01-14 2010-07-22 Nutrafood Nutrients, Inc. Consumable dissolving film comprising active ingredients derived from bacteria and fungi
US8701671B2 (en) 2011-02-04 2014-04-22 Joseph E. Kovarik Non-surgical method and system for reducing snoring
US9549842B2 (en) 2011-02-04 2017-01-24 Joseph E. Kovarik Buccal bioadhesive strip and method of treating snoring and sleep apnea
DE102010009071A1 (de) 2010-02-23 2011-10-06 Optimags Dr. Zimmermann Gmbh Essbare Folie und Verfahren zum Herstellen einer solchen
CN102078637A (zh) * 2011-01-26 2011-06-01 西北师范大学 海藻酸钠/罗望子胶共混载药膜及其制备方法和用途
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US20220296500A1 (en) * 2011-02-04 2022-09-22 Seed Health, Inc. Method and System for Preventing Sore Throat in Humans
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
BR112014014361A2 (pt) * 2011-12-16 2017-06-13 Colgate Palmolive Co composições orais com alteração de cor contendo filme
WO2014000803A1 (de) 2012-06-28 2014-01-03 Optimags Dr. Zimmermann Gmbh Verfahren zur herstellung einer folienformulierung für eine essbare folie und deren verwendung
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
CN105962377B (zh) * 2016-05-06 2019-03-19 华侨大学 一种携载高活性益生菌可食膜的制备方法
CN106822572A (zh) * 2017-03-22 2017-06-13 褚金涛 一种用于咽炎的中成药及其制备工艺
GB201709865D0 (en) * 2017-06-20 2017-08-02 Sugarfayre Ltd Sugar Paste
EP3755310A4 (en) * 2018-02-22 2021-05-19 Avior, Inc. TRANSMUCOSAL FILM COMPOSITION AND METHOD OF MANUFACTURING AND USING THEREOF
WO2020055547A2 (en) 2018-08-18 2020-03-19 Seed Health, Inc. Methods and compositions for honey bee health
CN110965391B (zh) * 2019-12-17 2020-12-25 浙江金龙再生资源科技股份有限公司 一种高强度白面牛卡纸的制造方法
WO2025064293A1 (en) * 2023-09-18 2025-03-27 R.P. Scherer Technologies, Llc Fast dissolving softgel capsules including ibuprofen

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US206942A (en) * 1878-08-13 Improvement in farm-gates
ZA767136B (en) * 1975-12-15 1977-10-26 Hoffmann La Roche Novel dosage form
JPS5758615A (en) * 1980-09-26 1982-04-08 Nippon Soda Co Ltd Film agnent and its preparation
JPH0729915B2 (ja) * 1986-02-01 1995-04-05 帝國製薬株式会社 シ−ト状口腔内貼付剤
US5196202A (en) * 1986-09-01 1993-03-23 Teikoku Seiyaku Kabushiki Kaisha Sustained release dosage form
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
JPH0645536B2 (ja) * 1989-01-31 1994-06-15 日東電工株式会社 口腔粘膜貼付剤および口腔粘膜貼付製剤
US20010006677A1 (en) * 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
GB9623634D0 (en) * 1996-11-13 1997-01-08 Bpsi Holdings Inc Method and apparatus for the coating of substrates for pharmaceutical use
DE19652257A1 (de) * 1996-12-16 1998-06-18 Lohmann Therapie Syst Lts Einzeln dosierte, bei Kontakt mit Flüssigkeit schnell zerfallende, wirkstoff- und insbesondere aromastoffhaltige, folienförmige Darreichnungsform
GB2328443B (en) * 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
CA2520986C (en) * 1998-09-25 2007-11-13 Warner-Lambert Company Physiological compatible film
US20030211136A1 (en) * 1998-09-25 2003-11-13 Neema Kulkarni Fast dissolving orally consumable films containing a sweetener
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US20030206942A1 (en) * 1998-09-25 2003-11-06 Neema Kulkarni Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent
US6210699B1 (en) * 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US7067116B1 (en) * 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
DE10032456A1 (de) * 2000-07-04 2002-01-31 Lohmann Therapie Syst Lts Schnell zerfallende Darreichungsform zur Freisetzung von Wirkstoffen im Mundraum oder in Körperhöhlen
US20020131990A1 (en) * 2000-11-30 2002-09-19 Barkalow David G. Pullulan free edible film compositions and methods of making the same
US6660292B2 (en) * 2001-06-19 2003-12-09 Hf Flavoring Technology Llp Rapidly disintegrating flavored film for precooked foods
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US8765167B2 (en) * 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
AU2002343734A1 (en) * 2001-11-16 2003-06-10 Givaudan Sa Edible film
US20040247649A1 (en) * 2002-02-11 2004-12-09 Edizone, Lc Medicine-containing orally soluble films
EP1542903B1 (en) * 2002-07-22 2015-05-20 MonoSolRX, LLC Packaging and dispensing of rapid dissolve dosage form
US20040043134A1 (en) * 2002-08-27 2004-03-04 Corriveau Christine Leclair Rolled edible thin film products and methods of making same
US20060205629A1 (en) * 2002-10-30 2006-09-14 Reg Macquarrie Edible dissolving gelatin strips
US8999372B2 (en) * 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
US20040096569A1 (en) * 2002-11-15 2004-05-20 Barkalow David G. Edible film products and methods of making same
CA2606724A1 (en) * 2005-05-03 2006-11-09 Innozen, Inc. Edible film for transmucosal delivery of nutritional supplements

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9931305B2 (en) 2001-10-12 2018-04-03 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8652378B1 (en) 2001-10-12 2014-02-18 Monosol Rx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US9855221B2 (en) 2001-10-12 2018-01-02 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8906277B2 (en) 2001-10-12 2014-12-09 Monosol Rx, Llc Process for manufacturing a resulting pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US11077068B2 (en) 2001-10-12 2021-08-03 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US10888499B2 (en) 2001-10-12 2021-01-12 Aquestive Therapeutics, Inc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US9108340B2 (en) 2001-10-12 2015-08-18 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US10111810B2 (en) 2002-04-11 2018-10-30 Aquestive Therapeutics, Inc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
WO2006029896A1 (de) * 2004-09-17 2006-03-23 Aquanova German Solubilisate Technologies (Agt) Gmbh Konservierungsmittel-zusammensetzungen
WO2008089151A3 (en) * 2007-01-12 2009-03-19 Monosol Rx Llc High dose film compositions and methods of preparation
WO2008107301A2 (fr) 2007-02-28 2008-09-12 Pierre Fabre Medicament Film monocouche a desintegration rapide pour l'administration buccale de substances actives
WO2008104076A1 (en) * 2007-03-01 2008-09-04 Aroll Exama Electrocolloidal silver and echinacea root antimicrobial formulation
WO2009066262A1 (en) * 2007-11-21 2009-05-28 The Procter & Gamble Company Preparations, methods and kits useful for treatment of cough
US9669020B2 (en) 2009-06-12 2017-06-06 Sunovion Pharmaceuticals Inc. Sublingual apomorphine
US9044475B2 (en) 2009-06-12 2015-06-02 Cynapsus Therapeutics, Inc. Sublingual apomorphine
US9326981B2 (en) 2009-06-12 2016-05-03 Cynapsus Therapeutics, Inc. Sublingual apomorphine
US10420763B2 (en) 2009-06-12 2019-09-24 Sunovion Pharmaceuticals Inc. Sublingual apomorphine
US9669019B2 (en) 2009-06-12 2017-06-06 Sunovion Pharmaceuticals Inc. Sublingual apomorphine
US9669021B2 (en) 2009-06-12 2017-06-06 Sunovion Pharmaceuticals Inc. Sublingual apomorphine
US9669018B2 (en) 2009-06-12 2017-06-06 Sunovion Pharmaceuticals Inc. Sublingual apomorphine
US10821074B2 (en) 2009-08-07 2020-11-03 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US10940626B2 (en) 2010-10-22 2021-03-09 Aquestive Therapeutics, Inc. Manufacturing of small film strips
US10272607B2 (en) 2010-10-22 2019-04-30 Aquestive Therapeutics, Inc. Manufacturing of small film strips
US9427412B2 (en) 2010-12-16 2016-08-30 Cynapsus Therapeutics, Inc. Sublingual films
US11419769B2 (en) 2010-12-16 2022-08-23 Sunovion Pharmaceuticals Inc. Sublingual films
US8846074B2 (en) 2010-12-16 2014-09-30 Cynapsus Therapeutics, Inc. Sublingual films
US8414922B2 (en) 2010-12-16 2013-04-09 Cynapsus Therapeutics, Inc. Sublingual films
US9283219B2 (en) 2010-12-16 2016-03-15 Cynapsus Therapeutics, Inc. Sublingual films
US10285953B2 (en) 2010-12-16 2019-05-14 Sunovion Pharmaceuticals Inc. Sublingual films
WO2012135559A1 (en) * 2011-03-31 2012-10-04 Mcneil-Ppc, Inc. Menthol liquids composition
ITMI20120510A1 (it) * 2012-03-29 2013-09-30 Bio Lo Ga Srl Vitamina e e suoi esteri per l'uso nel trattamento topico di affezioni faringo-laringee
WO2013167742A1 (fr) 2012-05-11 2013-11-14 Pierre Fabre Medicament Film monocouche a desintegration rapide et son utilisation dans l'hygiene buccale
JP2012207031A (ja) * 2012-07-02 2012-10-25 Rohto Pharmaceutical Co Ltd 粘膜適用組成物
US9439872B2 (en) 2014-08-27 2016-09-13 Nitto Denko Corporation Oral film-form base and preparation
EP2990030A1 (en) 2014-08-27 2016-03-02 Nitto Denko Corporation Oral film-form base and preparation
KR20160025468A (ko) 2014-08-27 2016-03-08 닛토덴코 가부시키가이샤 구강 내 필름형 기제 및 제제
JP2015091888A (ja) * 2015-02-10 2015-05-14 ロート製薬株式会社 粘膜適用組成物
US10449146B2 (en) 2015-04-21 2019-10-22 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
US10959943B2 (en) 2015-04-21 2021-03-30 Sunovion Pharmaceuticals Inc. Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa
JP2016121189A (ja) * 2016-04-01 2016-07-07 ロート製薬株式会社 粘膜適用組成物
US12023309B2 (en) 2016-05-05 2024-07-02 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11191737B2 (en) 2016-05-05 2021-12-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11723863B2 (en) 2018-06-22 2023-08-15 Church & Dwight Co., Inc. Oral care compositions comprising benzocaine and mucoadhesive thin films formed therefrom
EP3810103A4 (en) * 2018-06-22 2022-02-16 Church & Dwight Co., Inc. Oral care compositions comprising benzocaine and mucoadhesive thin films formed therefrom
AU2019396829B2 (en) * 2018-12-11 2025-04-17 Myospots Australia Pty Ltd Adhesive pad
EP3893823A4 (en) * 2018-12-11 2022-11-02 Myospots Australia Pty Ltd Adhesive pad
US12458607B2 (en) 2018-12-11 2025-11-04 Myospots Australia Pty Ltd Adhesive pad
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
WO2025106972A1 (en) * 2023-11-17 2025-05-22 Teeth Tabs PLLC Tableted effervescing dental treatment composition, and methods

Also Published As

Publication number Publication date
MXPA06002022A (es) 2006-10-01
EP1560571A2 (en) 2005-08-10
AU2003295577A1 (en) 2004-06-15
CA2505833A1 (en) 2004-06-03
EP1560571A4 (en) 2007-11-28
AU2003295577A8 (en) 2004-06-15
MXPA05005243A (es) 2006-03-10
US20040136923A1 (en) 2004-07-15
JP2006515598A (ja) 2006-06-01
WO2004045537A3 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
US20040136923A1 (en) Edible film for relief of cough or symptoms associated with pharyngitis
US10398644B2 (en) Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US9155698B2 (en) Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US8840935B2 (en) Orally administrable films and preparation thereof
CA2515006C (en) Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
WO2009052421A1 (en) Composition for administering an active ingredient and method for making and using the same
US9561182B2 (en) Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
DE69930964T2 (de) Zusammensetzungen und verfahren für mukosale abgabe
CA2169729C (en) Water-soluble pressure-sensitive mucoadhesive
JPS62178513A (ja) シ−ト状口腔内貼付剤
JP2007077142A (ja) 可溶性フィルム
RU2445977C2 (ru) Водорастворимые пленки, содержащие маловязкие альгинаты
TW201717915A (zh) 固態製劑之外層用組成物及含有該外層用組成物之易服用性固態製劑
WO2009055846A1 (en) Improved tablet coating
JPWO2005084703A1 (ja) 徐放性の口腔用組成物
CN101495101B (zh) 糖衣制剂及其制造方法
US20190167578A1 (en) Transmucosal Delivery of Terpenes Via Edible Film
Dave et al. A review on promising novel drug delivery system-bioadhesive drug delivery system
CN108463216A (zh) 口腔内保持型崩解性固体制剂、其制造方法和用于该制造方法的粉体组合物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/005243

Country of ref document: MX

Ref document number: 2505833

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004570422

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003786775

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003786775

Country of ref document: EP